Your session is about to expire
← Back to Search
Unknown
BT-11 880 mg for Crohn's Disease
Phase 2
Waitlist Available
Research Sponsored by Landos Biopharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects aged 18 to 75 years with a diagnosis of CD for at least 3 months;
Moderately to severely active CD as defined by: a CDAI score of 220 450, and an SES-CD scored ≥ 6 ( ≥ 4 for isolated ileitis) (centrally read);
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Study Summary
This study is evaluating whether a drug called BT-11 can help people with Crohn's disease.
Eligible Conditions
- Crohn's Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clinical Remission Rate
Secondary outcome measures
Clinical response
Endoscopic Response
Endoscopic remission
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: BT-11 880 mgExperimental Treatment1 Intervention
Oral once daily tablet
Group II: PlaceboPlacebo Group1 Intervention
Oral once daily tablet
Find a Location
Who is running the clinical trial?
Landos Biopharma Inc.Lead Sponsor
8 Previous Clinical Trials
499 Total Patients Enrolled
NImmune BiopharmaLead Sponsor
5 Previous Clinical Trials
324 Total Patients Enrolled
Jyoti ChauhanStudy DirectorLandos Biopharma Inc.
6 Previous Clinical Trials
349 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger